{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:03:31Z","timestamp":1763705011666},"reference-count":26,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.3892\/ol.2014.2810","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T12:38:28Z","timestamp":1418819908000},"page":"1313-1316","source":"Crossref","is-referenced-by-count":3,"title":["T-cell lymphoma with POEMS syndrome"],"prefix":"10.3892","volume":"9","author":[{"given":"FANGWEN","family":"ZOU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZHENHUA","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIN-AN","family":"MA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZHENHUA","family":"QIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YI-FANG","family":"TANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIAO-YUN","family":"ZHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,12,17]]},"reference":[{"key":"key20180108102639_b1-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large cell lymphoma): Results from the Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"key":"key20180108102639_b2-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00005792-198007000-00006","article-title":"Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature","volume":"59","author":"Bardwick","year":"1980","journal-title":"Medicine (Baltimore)"},{"key":"key20180108102639_b3-ol-09-03-1313","first-page":"157","article-title":"A narrative review of manual muscle testing and implications for muscle testing research","volume":"10","author":"Conable","year":"2011","journal-title":"J Chiropr Med"},{"key":"key20180108102639_b4-ol-09-03-1313","article-title":"World Health Organization Classification of Tumors","volume-title":"Pathology and Genetics, Tumors of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"key20180108102639_b5-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: definitions and long-term outcome","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"key":"key20180108102639_b6-ol-09-03-1313","first-page":"206","article-title":"Angioimmunoblastic T-cell lymphoma as a very poor-prognosis malignancy - a single centre experience","volume":"25","author":"Vokurka","year":"2012","journal-title":"Klin Onkol"},{"key":"key20180108102639_b7-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project: International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180108102639_b8-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Groupe d\u2019Etude des Lymphomes de l\u2019Adulte: Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within Groupe d\u2019 Etude des-Lymphoms de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"key20180108102639_b9-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A systematie review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"key":"key20180108102639_b10-ol-09-03-1313","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"key":"key20180108102639_b11-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.2009.24.4905","article-title":"High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Kyriakou","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180108102639_b12-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: result from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180108102639_b13-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"key":"key20180108102639_b14-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/hon.2038","article-title":"Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up","volume":"31","author":"Fabbri","year":"2013","journal-title":"Hematol Oncol"},{"key":"key20180108102639_b15-ol-09-03-1313","first-page":"332","article-title":"Therapeutic efficacy of cyclosporin A for refractory angiommunoblastic T cell lymphoma","volume":"51","author":"Mori","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"key20180108102639_b16-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12288-011-0077-z","article-title":"The outcome of hyperCVAD combined with alemtuzumab for the treatment of aggressive T-cell and NK-cell neoplasms","volume":"27","author":"Kuan","year":"2011","journal-title":"Indian J Hematol Blood Transfus"},{"key":"key20180108102639_b17-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"key20180108102639_b18-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/annonc\/mdm579","article-title":"Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab","volume":"19","author":"Aguiar Bujanda","year":"2008","journal-title":"Ann Oncol"},{"key":"key20180108102639_b19-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.seminhematol.2013.11.008","article-title":"Angioimmunoblastic T-cell lymphoma management","volume":"51","author":"Mosalpuria","year":"2014","journal-title":"Semin Hematol"},{"key":"key20180108102639_b20-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jnnp.2007.125930","article-title":"Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis?","volume":"79","author":"Viala","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20180108102639_b21-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-0609.2009.01307.x","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type, with features simulating POEMS syndrome","volume":"84","author":"Nakayama","year":"2010","journal-title":"Eur J Haematol"},{"key":"key20180108102639_b22-ol-09-03-1313","first-page":"1621","article-title":"POEMS syndrome complicated by follicular lymphoma","volume":"50","author":"Sasaki","year":"2009","journal-title":"Rinsho Ketsueki"},{"key":"key20180108102639_b23-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T-cells","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"key20180108102639_b24-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2169\/internalmedicine.50.4386","article-title":"Aberrant CD20 expression in angioimmunoblastic T-cell lymphoma","volume":"50","author":"Tachibana","year":"2011","journal-title":"Intern Med"},{"key":"key20180108102639_b25-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"key":"key20180108102639_b26-ol-09-03-1313","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA","volume":"97","author":"Delfau-Larue","year":"2012","journal-title":"Haematologica"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2014.2810\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T13:18:36Z","timestamp":1515417516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2014.2810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,17]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,12,17]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.3892\/ol.2014.2810"],"URL":"https:\/\/doi.org\/10.3892\/ol.2014.2810","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,17]]}}}